AEterna Zentaris Inc (AEZS)

3.05
0.05 1.61
NASDAQ : Health Care
Prev Close 3.10
Open 3.10
Day Low/High 3.00 / 3.15
52 Wk Low/High 2.60 / 21.20
Volume 133.02K
Avg Volume 224.40K
Exchange NASDAQ
Shares Outstanding 14.10M
Market Cap 43.72M
EPS -2.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Dow Leads Wall Street as Financials Stocks Stage a Small Rebound

Dow Leads Wall Street as Financials Stocks Stage a Small Rebound

The Dow Jones Industrial Average shakes off recent weakness to post modest gains as a financials stocks stage a slight rebound.

U.S. Stocks Climb to Session Highs as Financials Make a Rebound

U.S. Stocks Climb to Session Highs as Financials Make a Rebound

Stocks add to earlier gains Thursday as the financial sector makes a slight rebound after recent weakness.

Stock Futures Pare Losses as U.S. Economy Grows Faster Than Anticipated in 4Q

Stock Futures Pare Losses as U.S. Economy Grows Faster Than Anticipated in 4Q

Stock futures pare losses on Thursday after the U.S. economy grows at a slightly faster pace than anticipated over the last three months of 2016.

Aeterna Zentaris Intends To File NDA With Respect To Macrilen™ In Third Quarter Of 2017

Aeterna Zentaris Intends To File NDA With Respect To Macrilen™ In Third Quarter Of 2017

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company") today announced that, following its meeting with the U.

Aeterna Zentaris Announces At The Market Issuance Program

Aeterna Zentaris Announces At The Market Issuance Program

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS): All dollar amounts are stated in US$ Aeterna Zentaris Inc.

Aeterna Zentaris Reports Fourth Quarter And Full-Year 2016 Financial And Operating Results

Aeterna Zentaris Reports Fourth Quarter And Full-Year 2016 Financial And Operating Results

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company"), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology and endocrinology, today reported financial and...

Aeterna Zentaris Announces EMA Pediatric Committee Agreement On The Pediatric Investigation Plan For Macrilen™

Aeterna Zentaris Announces EMA Pediatric Committee Agreement On The Pediatric Investigation Plan For Macrilen™

Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZS) (the "Company") announced today that the Pediatric Committee ("PDCO") of the European Medicines Agency ("EMA") agreed to the Company's Pediatric Investigation Plan...

Aeterna Zentaris To Announce Fourth Quarter And Full-Year 2016 Financial And Operating Results On March 15, 2017

Aeterna Zentaris To Announce Fourth Quarter And Full-Year 2016 Financial And Operating Results On March 15, 2017

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (the "Company") will announce its fourth quarter and full-year 2016 financial and operating results after market close on Wednesday, March 15, 2017.

Aeterna Zentaris Announces Presentation Regarding Macrilen™ At 99th Annual Meeting Of The Endocrine Society

Aeterna Zentaris Announces Presentation Regarding Macrilen™ At 99th Annual Meeting Of The Endocrine Society

Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZ) (the "Company") today announced that Jose M.

Aeterna Zentaris Announces Zoptrex™ Presentation In Prostate Cancer At 2017 Genitourinary Cancers Symposium

Aeterna Zentaris Announces Zoptrex™ Presentation In Prostate Cancer At 2017 Genitourinary Cancers Symposium

Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZ) (the "Company") today announced that a poster entitled, "A phase II trial of zoptarelin doxorubicin in castration-and taxane-resistant prostate cancer", will be presented...

Aeterna Zentaris Announces Plans To Pursue FDA Registration Of Macrilen™

Aeterna Zentaris Announces Plans To Pursue FDA Registration Of Macrilen™

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that, following a comprehensive review of data obtained from the confirmatory Phase 3 clinical trial of Macrilen™ (macimorelin) for the...

Aeterna Zentaris To Present At The 2nd Annual Disruptive Growth & Healthcare Conference

Aeterna Zentaris To Present At The 2nd Annual Disruptive Growth & Healthcare Conference

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company"), announced today that it will be presenting at the 2nd Annual Disruptive Growth & Healthcare Conference on Thursday, February 16 at 9:30 AM EST.

Aeterna Zentaris To Present At The 2017 BIO CEO And Investor Conference

Aeterna Zentaris To Present At The 2017 BIO CEO And Investor Conference

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it will be presenting at the 2017 BIO CEO & Investor Conference on Monday, February 13 at 8:00 AM EST in New York City.

Aeterna Zentaris Announces Completion Of Zoptrex™ Pivotal Phase 3 Clinical Trial In Advanced Endometrial Cancer; Expects To Report Top-Line Results In April 2017

Aeterna Zentaris Announces Completion Of Zoptrex™ Pivotal Phase 3 Clinical Trial In Advanced Endometrial Cancer; Expects To Report Top-Line Results In April 2017

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the occurrence of the 384 th death in the pivotal Phase 3 ZoptEC ( Zoptarelin Doxorubicin in Endometrial Cancer) study with Zoptrex™...

Aeterna Zentaris Announces Top-Line Results Of Confirmatory Phase 3 Trial Of Macrilen™

Aeterna Zentaris Announces Top-Line Results Of Confirmatory Phase 3 Trial Of Macrilen™

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the confirmatory Phase 3 clinical trial of Macrilen™ (macimorelin) failed to achieve its objective of validating a single oral dose...

Aeterna Zentaris Reports Third Quarter 2016 Financial And Operating Results

Aeterna Zentaris Reports Third Quarter 2016 Financial And Operating Results

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology and endocrinology, today reported financial and...

Aeterna Zentaris Announces Closing Of US$7,560,000 Registered Direct Offering Of Common Shares And Warrants

Aeterna Zentaris Announces Closing Of US$7,560,000 Registered Direct Offering Of Common Shares And Warrants

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the closing of its previously announced registered direct offering to a single healthcare dedicated institutional investor in the...

Aeterna Zentaris To Announce Third Quarter 2016 Financial And Operating Results On November 8, 2016

Aeterna Zentaris To Announce Third Quarter 2016 Financial And Operating Results On November 8, 2016

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its third quarter 2016 financial and operating results after market close on Tuesday, November 8, 2016.

Aeterna Zentaris Announces US$7,560,000 Registered Direct Offering Of Common Shares And Warrants

Aeterna Zentaris Announces US$7,560,000 Registered Direct Offering Of Common Shares And Warrants

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZ) (the "Company") today announced that it is raising US$7,560,000 in gross proceeds in a registered direct offering to a single healthcare dedicated institutional investor in...

Aeterna Zentaris Completes Patient Recruitment For Confirmatory Phase 3 Trial Of Macrilen™

Aeterna Zentaris Completes Patient Recruitment For Confirmatory Phase 3 Trial Of Macrilen™

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced it has successfully completed patient recruitment for the confirmatory Phase 3 clinical trial of Macrilen™ (macimorelin) as a growth...

Aeterna Zentaris And Specialised Therapeutics Asia Sign Exclusive License Agreement For The Potential Marketing Of Zoptrex™ In Australia And New Zealand

Aeterna Zentaris And Specialised Therapeutics Asia Sign Exclusive License Agreement For The Potential Marketing Of Zoptrex™ In Australia And New Zealand

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") and Specialised Therapeutics Asia ("STA") today announced the signing of an exclusive license agreement for the Company's lead investigational anti-cancer...

Aeterna Zentaris Announces Expiration Of Remaining Series B Warrants

Aeterna Zentaris Announces Expiration Of Remaining Series B Warrants

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that the remaining 8,064 Series B Common Share Purchase Warrants (the "Series B Warrants") issued in connection with the Company's March 2015...

Aeterna Zentaris To Present At Upcoming Aegis Capital Corp. 2016 Growth Conference In Las Vegas, Nevada

Aeterna Zentaris To Present At Upcoming Aegis Capital Corp. 2016 Growth Conference In Las Vegas, Nevada

Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZ) (the "Company") today announced that the Company's President and Chief Executive Officer, David Dodd, will present a corporate overview at the Aegis Capital Corp.

Aeterna Zentaris To Present At Upcoming Rodman & Renshaw Annual Global Investment Conference In New York

Aeterna Zentaris To Present At Upcoming Rodman & Renshaw Annual Global Investment Conference In New York

Aeterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ) (the "Company") today announced that the Company's President and Chief Executive Officer, David Dodd, will present a corporate overview at the Rodman & Renshaw 18th Annual...

Aeterna Zentaris Reports Second Quarter 2016 Financial And Operating Results

Aeterna Zentaris Reports Second Quarter 2016 Financial And Operating Results

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a specialty biopharmaceutical company engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health, today reported...

Aeterna Zentaris Expands Promotion Of APIFINY® Into Florida

Aeterna Zentaris Expands Promotion Of APIFINY® Into Florida

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced that it is expanding its promotion of APIFINY ®, the only cancer-specific, non-PSA blood test available to assess the risk for the...

Aeterna Zentaris And Rafa Laboratories Sign Exclusive License Agreement For Zoptrex™ In Israel

Aeterna Zentaris And Rafa Laboratories Sign Exclusive License Agreement For Zoptrex™ In Israel

Aeterna Zentaris Inc. (NASDAQ: AEZS)(TSX: AEZ) (the "Company") and Rafa Laboratories, Ltd.

Aeterna Zentaris To Announce Second Quarter 2016 Financial And Operating Results On August 9, 2016

Aeterna Zentaris To Announce Second Quarter 2016 Financial And Operating Results On August 9, 2016

Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") will announce its second quarter 2016 financial and operating results after market close on Tuesday, August 9, 2016.